|
- Lillys oral GLP-1, orforglipron, demonstrated statistically . . .
Chugai and Lilly published the preclinical pharmacology data of this molecule together 6 Lilly is running Phase 3 studies on orforglipron for the treatment of type 2 diabetes and for weight management in adults with obesity or overweight with at least one weight-related medical problem
- Eli Lillys Next-Generation Weight Loss Drug: Retatrutide Set for Early . . .
In conclusion, Eli Lilly's next-generation weight loss drug, retatrutide, is set for an early release in 2025, with promising results from phase 2 trials indicating significant weight loss and a favorable safety profile
- Eli Lillys New Weight Loss Pill May Be Available Next Year
A GLP-1 in pill form from Eli Lilly shows promising results for weight loss and Type 2 diabetes treatment in a trial FDA approval is expected in 2026
- Trial: Eli Lilly obesity pill orforglipron led to over 12% weight loss
Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market for weight loss and diabetes drugs
- Lilly shows findings of new weight loss drug orforglipron; stock booms
Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at certain dosages
- Eli Lilly to Release Retatrutide Weight Loss Drug Data in 2025
Eli Lilly Co has announced plans to release data from a late-stage trial of its next-generation weight loss drug, retatrutide, in 2025—several months earlier than previously expected The company anticipates sharing results from a 68-week study involving individuals with obesity and knee osteoarthritis, with data set to be unveiled in 2025
- Eli Lilly Advances Weight Loss Drug Development and Alzheimer’s . . .
Eli Lilly has announced it will release data from a “late-stage trial” of its weight loss drug, retatrutide, ahead of its initial planned release date in February 2026
- Oral Weight Loss Drug Shows 27-Pound Loss in Lilly Phase 3 Trial | LLY . . .
First oral GLP-1 drug achieves 27 3-pound weight loss in pivotal trial Lilly plans year-end FDA submission for once-daily pill See full efficacy data
|
|
|